Help-Line 01233 334879

 

Proventus

Making Life Fairer

 

Working Together to Make a Difference

UK Charity No 1131517

Working together to make a difference

We are a member of the Fund Raising Standards Board

 

We are all volunteers and the advice we receive is also given freely.

 

All donations are used to further the work we do.

Please Donate

 

Join Us

 

Provide Support

Buy At

 

UK Charity

No 1131517

 

Copyright © Proventus 2010

 

Terms & Conditions

 

Multiple Sclerosis

It is important to remember that MS is only one part of a person and not the person.

MS does not represent them, it is not their identity, they are as normal as the next person.  

Find Us Here

Risk-sharing Scheme                                                                                                                                                                                

The mechanism that makes the disease modifying drugs - Beta interferon - Glatiramer acetate - Copaxone® available on the NHS to people with certain types of MS.

 

Prior to the scheme provision varied widely between areas. The scheme was set up by the Department of Health to address these inequalities and also in the light of an assessment by the National Institute of Health and Clinical Excellence (NICE), which judged the drugs not to be cost effective. Under the scheme, all those with relapsing - remitting MS, and those with secondary progressive MS in which relapses are the dominant feature will be eligible for the drugs if they meet the criteria laid down by the Association of British Neurologists (ABN) in 2001,.

 

The 'risk' element of the Scheme involves a sharing of the financial risk between the NHS and the participating pharmaceutical companies.

 

Prescription criteria - 2001 guidelines                                                                                                                                                   

• People with relapsing/remitting MS should - be able to walk at least 100 metres without assistance, have had at least two clinically significant relapses in the last two years and be aged 18 or over.
• People with secondary progressive MS should be able to walk at least 10 metres with or without assistance have had at least two disabling relapses in the last two years and have had minimal increase in disability due to gradual progression over the last two years and be aged 18 or over.

 

Women that are pregnant or who are breastfeeding and those who are attempting to become pregnant should not take these drugs. There are also criteria for stopping treatment if the drugs are no longer effective.

 

2007 guidelines                                                                                                                                                                                          

The ABN has since revised its prescription criteria to allow for prescribing at an earlier stage following diagnosis.

 

During November 2008, in the light of subsequent changes with new and existing medications, the ABN announced that it had withdrawn the 2007 guidelines for immediate review. The 2001 guidelines remain the basis for the prescription criteria for the disease modifying drugs.

 

The 2007 Guidelines had suggested the following prescription criteria:

 

To begin treatment, an individual must:

• Be able to walk, without or without assistance such as a stick.
• Have a confirmed MS diagnosis with a relapsing onset  - ie Relapsing - Remitting MS at onset.
• Be aged 18 or over - treatment of younger people may be undertaken in some cases.

 

Eligibility                                                                                                                                                                                                     

1. Diagnosis of MS by the McDonald criteria within one year of presentation with a clinically isolated syndrome - beta interferon only.

Or

1. Relapsing - Remitting MS - beta interferon or glatiramer acetate - copaxone® - with active disease, defined as one or more of two clinically significant relapses in the past two years.

Or

1. One disabling relapse in the past year

Or

1. Active MRI scan containing new or gadolinium enhancing lesions that have developed in the past year - usually the individual must also be experiencing relapses

Or

1. Secondary Progressive MS - beta interferon, only  recommended when relapses are the main cause of increasing disability.

 

 

Top of Page